Lymphocyte infusion for delayed extramedullary relapse of acute leukemia following bone marrow transplantation

Leukemia & Lymphoma
D R FlemingE H Romond

Abstract

We report a case of extramedullary relapse of acute myelogenous leukemia twelve years after allogeneic bone marrow transplantation. Due to the localized nature of the relapse, we were able to eliminate a majority of the tumor burden, utilizing local irradiation. Destined with eventual systemic leukemia relapse, further therapy utilizing donor lymphocytes was given at a time of minimal disease burden. The patient remains in a state of complete remission.

References

Jan 15, 1992·Cancer·J A SpinoloA R Zander
Feb 1, 1990·The New England Journal of Medicine·K E AndersonR B Stead
Jan 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J MortimerE D Thomas
Jul 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J C ByrdN A Dawson
Mar 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B M BärT De Witte

❮ Previous
Next ❯

Citations

Jun 21, 2007·AJR. American Journal of Roentgenology·Jan FritzMarius Horger
Aug 8, 1998·British Journal of Haematology·J M Chessells
Dec 29, 1999·Leukemia & Lymphoma·W Y AuR Liang
Oct 27, 2006·Leukemia & Lymphoma·Isabel Cunningham
Jun 28, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Melhem SolhDan S Kaufman
Feb 18, 2010·Journal of Thoracic Imaging·Jason Tsai, Edward Y Lee
Mar 21, 2019·Radiology and Oncology·Hans-Jonas MeyerAlexey Surov
Dec 15, 2020·Critical Reviews in Oncology/hematology·Isabel Cunningham

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.